Clinical Myeloma Registry GMMG

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00026970

Enrollment

999

Registered

2023-04-03

Start date

2022-12-08

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C.90.0

Interventions

Group 1: Therapy-requiring multiple myeloma Previous participation in a drug study by the GMMG study group

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Multiple myeloma requiring treatment Prior participation in a drug study of the GMMG study group

Exclusion criteria

Exclusion criteria: Patients who have organ amyloidosis at the time of diagnosis

Design outcomes

Secondary

Measure	Time frame
Progression-Free Survival Response rates (remission rates and duration) Occurrence of secondary malignancies	—

Primary

Measure	Time frame
Overall Survival	—

Countries

Germany

Contacts

Public ContactGMMG-Studiensekretariat

Universitätsklinikum Heidelberg

studiensekretariat.GMMG@med.uni-heidelberg.de+49 6221 56 8198

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026